IRON DISC MEDICINE INC

Disc Medicine to Participate in the Jefferies Healthcare Conference

Disc Medicine to Participate in the Jefferies Healthcare Conference

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 9:30 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit

Media Contact

Peg Rusconi

Verge Scientific Communications

Investor Relations Contact

Suzanne Messere

Stern Investor Relations



EN
31/05/2023

Underlying

IRONDISC MEDICINE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Reports First Quarter 2025 Financial Results and Provide...

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPPPlan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025Expect data readouts for DISC-0974 program in H2 2025, including initial results of Phase 2 anemia of myelofibrosis (MF) study and multiple dose data from Phase 1b anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) ...

8h / 39m 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of My...

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a virtual KOL investor event on Friday, May 9 at 1:00 PM ET / 10:00 AM PT to provide an overview of anemia of myelofibrosis (MF) and discuss the evolving treatment landscape for this disease. The event will al...

April 29, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Resu...

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025Positive data from initial cohorts of ongoing Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependen...

February 27, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, MA): Corporate presentation on Wednesday, March 5th at 9:10 a.m. ET.Leerink Global Healthcare Conference (Miami, FL):...

February 26, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offer...

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of i...

January 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch